ArticleHealth economics review2023

Cost-utility analysis of Palbociclib + letrozole and ribociclib + letrozole versus Letrozole monotherapy in the first-line treatment of metastatic breast cancer in Iran using partitioned survival model.

Ali Darvishi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.